Previous Close | 11.30 |
Open | 11.30 |
Bid | 5.00 |
Ask | 8.30 |
Strike | 600.00 |
Expire Date | 2025-06-20 |
Day's Range | 11.30 - 11.30 |
Contract Range | N/A |
Volume | |
Open Interest | 3 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.